November is Alzheimer's Awareness Month, and recent developments in treatment offer renewed hope for patients and their families. An FDA-approved drug, Kisunla (lecanemab), is now available as a monthly infusion that targets and breaks down amyloid plaques in the brain, a hallmark of Alzheimer's disease.
Clinical Trial Insights
Clinical trials have shown promising results with Kisunla. One patient, Jerry Bello, who tested positive for the gene for dementia and had amyloid plaque buildup, participated in a double-blind study. Another participant, Connie Hagelin, enrolled in the trial when she experienced increased difficulty managing daily tasks. Both patients reported feeling improvements in their cognitive function during the trial.
The FDA cleared Eli Lilly's monthly infusions for use by adults with mild cognitive impairment in July after research showed a promising slowing of decline in memory and thinking abilities.
Mechanism of Action and Potential Side Effects
Kisunla is designed to remove amyloid plaques, which are believed to contribute to the progression of Alzheimer's disease. During the clinical trials, some patients experienced brain bleeds, a known side effect associated with anti-amyloid drugs. According to trial participants, the drug pulls the amyloids through the blood vessel, and as it does a little tiny bit of blood escapes. However, participants like Hagelin did not find this side effect alarming, emphasizing the potential benefits of the treatment.
The Future of Alzheimer's Treatment
Researchers are exploring the potential of anti-amyloid drugs like Kisunla to prevent the onset of Alzheimer's symptoms if administered early, before significant cognitive decline occurs. Dr. Michelle Papka, founder of the Cognitive Research Center of New Jersey, emphasized the excitement surrounding the drug's approval and its potential to modify the course of the disease. She also highlighted ongoing studies investigating the use of these drugs in individuals with early signs of the disease to potentially prevent the development of full-blown Alzheimer's.
Call to Action
Experts are encouraging individuals to get screened for early signs of Alzheimer's and to consider participating in clinical trials to contribute to the ongoing research efforts. The availability of new treatments like Kisunla and the continued dedication to research offer hope for finding a cure and improving the lives of those affected by this devastating disease.
